Related Experiment Video
Updated: Aug 24, 2026

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis
Tetsunari Kihira1, Junko Sato, Taro Shibata
1Pharmaceuticals and Medical Devices Evaluation Center, National Institute of Health Sciences, Toranomon 33 Mori Building, 10F, 3-8-21 Toranomon, Minato-ku, Tokyo 105-8409, Japan. kihira@nihs.go.jp
Abstract:
Based on the pharmacokinetic-pharmacodynamic (PK-PD) parameters of ciprofloxacin in rhesus monkeys, the efficacies of levofloxacin, sparfloxacin, norfloxacin, and tosufloxacin against anthrax in humans were examined. The optimal PK-PD parameter for the prophylaxis or treatment of infection with Bacillus anthracis is not clearly defined. To evaluate the efficacy of fluoroquinolones against anthrax, PK-PD parameters and the protein-binding effect of fluoroquinolones are used. B. anthracis is very susceptible to fluoroquinolones in vitro, and levofloxacin, sparfloxacin, and tosufloxacin may be as effective against anthrax as ciprofloxacin by PK-PD analysis. However, additional studies of the in vivo model are necessary to define more clearly efficacy against anthrax and the pharmacodynamic relationship of fluoroquinolones.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Inhalation Anthrax
Pharmacodynamic Models: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacodynamic Models: Linear Concentration–Effect Model

